Vickie S. Wilson EDVMS Meeting December 10-12-2003 Vickie S. Wilson EDVMS Meeting December 10-12-2003 Androgen Receptor Binding Assay Update.

Slides:



Advertisements
Similar presentations
LAB 3 Enzyme Kinetics Studying -galactosidase activity at varying substrate concentrations in the presence and absence of an inhibitor Michaelis-Menten.
Advertisements

Radioimmunoassay (RIA)
SPH 247 Statistical Analysis of Laboratory Data 1April 2, 2013SPH 247 Statistical Analysis of Laboratory Data.
1 Mechanism Testing of the Drug (Modified Megestrol) Mr.Pasavi Ratchapongsirikul.
Protein Binding Phenomena Lecture 7, Medical Biochemstry.
STRATUS CONSULTING The Biotic Ligand Model: Unresolved Scientific Issues and Site- and Species-specific Effects on Predicted Cu Toxicity Jeffrey Morris,
BISC 220 Lab 2 Protein Purification by Affinity Chromatography & Determination of Specific Activity.
Endocrine Screening – Phase 1 TSCA 8(e) and FIFRA 6(a)(2) Requirements A. Michael Kaplan, Ph.D. December 13, 2010 A. Michael Kaplan & Associates, LLC
Dose response relationships –A graph describing the response of an organism, population, or biological community to a range of concentrations of a xenobiotic.
L Berkley Davis Copyright 2009 MER301: Engineering Reliability Lecture 14 1 MER301: Engineering Reliability LECTURE 14: Chapter 7: Design of Engineering.
Luddite: An Information Theoretic Library Design Tool Jennifer L. Miller, Erin K. Bradley, and Steven L. Teig July 18, 2002.
Substances foreign to the body, such as disease-causing bacteria and viruses and other infectious agents, known as antigens, are recognized by the body's.
A Comparison of System Dynamics and Agent-Based Simulation Applied to the Study of Cellular Receptor Dynamics Edward J. Gallaher Behavioral Neuroscience,
Timed. Transects Statistics indicate that overall species Richness varies only as a function of method and that there is no difference between sites.
Chemometrics Method comparison
In Vitro Aromatase Assay: Prevalidation Studies
Mapping of Calmodulin Binding Sites on the IP 3 R1 N. Nadif Kasri, I. Sienaert, J.B. Parys, G. Callewaert, L. Missiaen and H. De Smedt Laboratory of Physiology,
Doing Research in Behavior Modification
Introduction to Design of Experiments
Design of Experiments Chapter 21.
Literature Review and Parts of Proposal
Science Research to Count On Al Frisby, M.S. & Dennis McCurdy, D.V.M.
Prevalidation Study Plan for Sliced Testes Assay Gary Timm Presented to EDMVS August 20, 2003.
Verification & Validation
HD 2007 Rule Diesel Fuel Sulfur Testing and Sampling Methods and Requirements US EPA Office of Transportation and Air Quality November 20, 2002.
Quantifying the drug-target binding affinity. Receptors as targets (Receptors are 45% of current drug targets) Receptors are areas of proteins found in.
A Bayesian Approach to Parallelism Testing in Bioassay
PHC 222 Part(I) Dr. Huda Al Salem Lecture (7). Factors that affect the efficacy 2- Concentration-Response Curves: Agonist Antagonist Partial agonist Desensetization.
Quality Control Lecture 5
Experimental Design If a process is in statistical control but has poor capability it will often be necessary to reduce variability. Experimental design.
Repeated Measurements Analysis. Repeated Measures Analysis of Variance Situations in which biologists would make repeated measurements on same individual.
DOX 6E Montgomery1 Unreplicated 2 k Factorial Designs These are 2 k factorial designs with one observation at each corner of the “cube” An unreplicated.
Receptors - Quantitation Quantitation of Receptor Occupation and Response for School of Biomedical Engineering, Drexel University Prof. Philip Lazarovici,
Biol 304 Week 3 Equilibrium Binding Multiple Multiple Binding Sites.
CENTER FOR BIOLOGICAL SEQUENCE ANALYSIS BiC BioCentrum-DTU Technical University of Denmark Cleavage sites and binding affinities.
CHEMISTRY ANALYTICAL CHEMISTRY Fall Lecture 6.
1 Exercise 7: Accuracy and precision. 2 Origin of the error : Accuracy and precision Systematic (not random) –bias –impossible to be corrected  accuracy.
Toxicological Knowledge Base (a Definition) Response Dose “ An in computero aggregated set of the most germane literature citations and biological activity.
Validation Defination Establishing documentary evidence which provides a high degree of assurance that specification process will consistently produce.
ISM Test Development Task Force Report June 21, 2004.
Mapping of Calmodulin binding sites on the IP3R1 N. Nadif Kasri; I. Sienaert, S. Vanlingen, J.B. Parys, G. Callewaert, L. Missiaen and H. De Smedt Laboratory.
PHARMACODYNAMICS M.T. Piascik PHA 824 November 11, 2008.
LECTURE 13 QUALITY ASSURANCE METHOD VALIDATION
Receptor Theory & Toxicant-Receptor Interactions Richard B. Mailman.
Advanced Higher Biology Unit 3 Investigative Biology.
Biological Evaluation Lecture - 4 Principles and Importance of BA’s Joseph O. Oweta B. Pharm (MUST)
Radioimmunoassay (RIA). RIA Purpose is to determine the concentration of an antigen in solution Competitive binding assay Originally developed by Yalow.
TIDEA Target (and Lead) Independent Drug Enhancement Algorithm.
MECH 373 Instrumentation and Measurement
i) Two way ANOVA without replication
Receptor Theory & Toxicant-Receptor Interactions
Shifting the Paradigm of Testosterone and Prostate Cancer: The Saturation Model and the Limits of Androgen-Dependent Growth  Abraham Morgentaler, Abdulmaged.
IE-432 Design Of Industrial Experiments
Gage R&R Estimating measurement components
Basic Training for Statistical Process Control
Parameters to be calculated
Basic Training for Statistical Process Control
Daniel Chi-Hong Lin, Alan D Grossman  Cell 
Yihan Wang, Michael A. Shia, Thomas G. Christensen, Steven C. Borkan 
Complement Receptor Type 1 (CR1, CD35) Is a Receptor for C1q
Autoradiographic mapping and characterization of insulin-like growth factor-I receptor binding in human greater saphenous vein  Anton N. Sidawy, MD, Fares.
Structure-Guided Design of Fluorescent S-Adenosylmethionine Analogs for a High- Throughput Screen to Target SAM-I Riboswitch RNAs  Scott F. Hickey, Ming C.
Complement Receptor Type 1 (CR1, CD35) Is a Receptor for C1q
Peter A. Savage, Mark M. Davis  Immunity 
Volume 89, Issue 5, Pages (May 1997)
Volume 96, Issue 3, Pages (February 1999)
Volume 92, Issue 6, Pages (March 1998)
Volume 62, Issue 2, Pages (August 2002)
Rinat Nahum-Levy, Dafna Lipinski, Sara Shavit, Morris Benveniste 
Drug- Receptor Interaction
Presentation transcript:

Vickie S. Wilson EDVMS Meeting December Vickie S. Wilson EDVMS Meeting December Androgen Receptor Binding Assay Update

Overview General introduction to binding assays NICEATM/ICCVAM and Expert Panel Summary of work completed  Training and Protocol Refinement  Comparison of RPC and PV  Scatchard analyses  R1881 comparison  16 chemicals Future Direction

Two basic types of receptor binding experiments Saturation Affinity of radioactive ligand for the receptor - K d - Affinity of radioligand - B max - Binding sites Competition Affinity of unlabeled ligand in competition with high affinity radioligand - IC50, RBA - K i – affinity of unlabeled ligand

Basic Steps in Receptor Binding Assays Receptor (R) + [3H]Ligand (Free)Receptor:Ligand Complex (Bound) k1k1 k2k2 Incubate R R 3H3H 3H3H R 3H3H 3H3H 3H3H 3H3H R 3H3H R 3H3H R Separate Bound from Free Measure Radioactivity Bound Analyze Results Radiolabeled ligand Test chemical R 3H3H Receptor [ T ] …

Competitive Binding Curve Quality Data

Example Binding Curves: Examine data carefully for problems

Experimental Determination of Competitive Inhibition and K i Double reciprocal plot Slope replot

EDC Expert Panel Report Acknowledged the lack of a standardized in vitro AR binding assay protocol Identified need for establishing comparative performance criteria Agreed on minimum procedural standards Acknowledged that RPC is “Gold Standard” for comparison purposes  Most frequently used - Particularly useful as a reference  Has several disadvantages Recommended as high priority the development of an assay using purified, recombinant full-length AR Patent issues with hAR so an assay using an AR sequence from a species closely related to human may be necessary

Overview General introduction to binding assays NICEATM/ICCVAM and Expert Panel Summary of work completed  Training and Protocol Refinement  Comparison of RPC and PV  Scatchard analyses  R1881 comparison  16 chemicals Future Direction

Comparison of RPC and PanVera Assays 2 Protocols Rat Ventral Prostate Cytosol (RPC) - from EPA, RTD PanVera - from NCTR Design: 3 Technicians Each tech ran every chemical in both protocols 2 Duplicate tubes per run (3 runs in dup) Positives were repeated by all 3 techs (6 runs) 19 Chemicals over a range of potencies Identified by number only Test chemical concentrations as specified in each protocol

Comparison of RPC and PV binding assays for R1881. The interassay CV for the PV assay is 13% versus 6% for the RPC assay. Hence the PV assay is 2 fold more variable, which will require more replicates.

Binding Curves Example of Variability between runs 6 runs of same chemical in both protocols RPC PV

PV Binding Assay for 3039 (DEHP) Comparison of RPC and PV for p,p’-DDE Examples Illustrating Concerns with PV Assay High Interassay Variability Binding Greater than 100% Comparison of RPC and PV for E2 U-Shaped CurveCurve Shifted

Analysis of Assay Comparison  High intra-assay variability in PV 3.5% of duplicates rejected. Discrepancy of greater than 25%  High inter-assay CV in PV assay Twice the rejection rate of the RPC  Several PV assays with extraordinarily high CVs  Other Issues Some U-Shaped binding curves in PV Binding greater than 100% in some PV assays  Different concentrations of unknowns used in RPC and PV assays complicates comparison of assays

Run Kd, nMBmax, fmol/mg 288J L J L Mean / / Saturation Binding Acceptable Two technicians Two Runs per technician Duplicates per run Runs on two different days

Reference Chemical (R1881) Comparison  2 Technicians each ran twice with duplicates – 4 reps (Subtask 3.2)  Repeated – 2 technicians; 6 runs each – 12 reps (Subtask 3.5) - Sixteen total replicates  Analysis was a nested ANOVA with a 5 x 2 x 8 x 2 design (5 concentrations of R1881; 2 techs; 8 replicates per tech; 2 duplicate observations per replicate)

Sigma Plots’s Ligand software R1881 Binding All runs converged and had R 2 values greater than 99%

EC50 and log EC50 by Run Shows clustering of results over time CV of reps (8) within batch = 4.6% CV between batches = 22.5% Note similarity of reps between 2 technicians

EC50 and log EC50 - Mean and SE “Batch” Clustering of Results Over Time All Three groups differ significantly from each other CV between batches = 22.5%

Summary and Conclusions R1881 R1881 Comparison Binding assay with R1881 was run 16 times in three “batches” by 2 technicians CV for duplicates – about 5% Interassay CV – about 22% Each run provided an excellent fit - R-squared values greater than 99% In the worst case, the IC50 values varied by 2 fold (0.7 X10 -9 to 1.3 X 10 -9) Success

Results of 16 Chemicals Original Report from Battelle classified 14 Chemicals as Binders 2 Chemicals as Non-Binders EPA Review reclassification 10 Binders 4 Equivocal 2 Non-binders Equivocal binders - need additional experiments to define Ki Chemicals were each run 2-3 times but better experimental design needed before detailed statistical analysis

4-tert- Octylphenol Methoxychlor Vinclozolin Procymidone Linuron Cyproterone Acetate 17  -Estradiol P,p’-DDE Medroxyprogesterone Acetate Methyltrienolone Testosterone Progesterone Dexamethasone Spironolactone BINDERS Atrazine Di(2-ethylhexyl)phthalate (DEHP) EQUIVOCAL NON-BINDERS

Recombinant Androgen Receptor Expert Panel recommended as high priority the development of an assay using purified, recombinant full-length AR - Patent issues with human AR - Species closely related to human Questions with truncated (chimeric) AR Ongoing work at EPA, RTD - Chimpanzee cDNA library obtained - Screening for full length AR

Future Direction Supplement binding data of 16 chemicals with additional runs and conduct statistical analysis (intralaboratory) Work on recombinant system is being conducted but lags behind desirable but 2-3 years for development and standardization no commercial or non-commercial source available Move forward with RPC assay standard data set comparative performance criteria interlaboratory study